A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumors Clinical Trial

Official title:

An Open-label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of MRG002 in Combination With HX008 in Patients With HER2-expressed Advanced Malignant Solid Tumors.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05338957
• Other study ID #: MRG002/HX008-C001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: August 5, 2022
• Est. completion date: December 2024

Study information

• Verified date: September 2022
• Source: Shanghai Miracogen Inc.
• Contact: Program Director
• Phone: 86-21-61637960
• Email: clinicaltrials[@]miracogen.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to determine the recommended phase II dose (RP2D) of combination therapy; , and to evaluate the preliminary efficacy, pharmacokinetics, and immunogenicity of combination therapy in the targeted study population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Willing to sign the informed consent form and follow the requirements specified in the protocol.

2. Aged 18 to 75 (including 18 and 75), both genders.

3. Life expectancy = 12 weeks.

4. Patients with histopathological or cytological confirmed HER2-expressed advanced solid tumors, and with at least one measurable lesion according to the Response Criteria in Solid Tumors (RECIST v1.1).

5. The score of ECOG for performance status is 0 or 1.

6. The toxicity of previous anti-tumor treatment has recovered to = Grade 1 as defined by NCI-CTCAEv5.0.

7. No severe cardiac dysfunction.

8. Organ functions must meet the basic requirements.

9. Cumulative dose of anthracycline = 450 mg/m2 doxorubicin or its equivalent.

Exclusion Criteria:

1. Prior treatment with chemotherapy, biological therapy, immunotherapy, radiotherapy, investigational drugs, attenuated live vaccines, immunomodulators, CYP3A4 inhibitors/inducers, antibody-drug conjugates, etc.

2. Treatment with immune checkpoint inhibitors or tumor vaccines within 60 days prior to the first dose.

3. Treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study period.

4. History of severe cardiac disease.

5. Poorly controlled hypertension and hyperglycemia.

6. Presence of peripheral neuropathy = Grade 2.

7. History of moderate or severe dyspnea at rest due to advanced malignant tumor or its complications or severe primary pulmonary disease, or current need of continuous oxygen therapy, or current interstitial lung disease or pneumonia.

8. Central nervous system metastasis.

9. Received major surgery within 4 weeks prior to the first dose without complete recovery.

10. History of hypersensitivity to any component of MRG002 or HX008 or known history of hypersensitivity of = Grade 3 to macromolecular protein products/monoclonal antibodies.

11. Evidence of active infection.

12. History of primary immunodeficiency or autoimmune disease.

13. Female patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 6 months after the last dose of study treatment.

14. Previous history of other primary malignancies.

15. Other conditions inappropriate for participation in this study, as deemed by the investigator.

Related Conditions & MeSH terms

• Advanced Malignant Solid Tumors
• Neoplasms

Intervention

Drug:
• MRG002+HX008
Administrated intravenously

Locations

Country	Name	City	State
China	Hunan Cancer Hospital	Changsha	Hunan
China	The Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	Shandong Cancer Hospital	Jinan	Shandong
China	Shanghai Oriental Hospital	Shanghai	Shanghai
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Miracogen Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose limiting toxicity (DLT) in each dose group	DLT is defined as any of the treatment emergent adverse events (TEAE) as specified in the protocol that bear a definite, probable, or possible causal relationship to study drug administration within 28 days after the first dose.	Within 28 days after the first dose.
Primary	Adverse events	Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.	After signing informed consent until 90 days after the last dose.
Primary	Recommended Phase II Dose (RP2D)	The dose level of MRG002 recommended for further clinical studies based on assessment of the safety, efficacy and PK data from this study.	Baseline to study completion (up to 24 months)
Secondary	Objective Response Rate (ORR)	ORR is defined as the proportion of subjects with CR and PR according to RECIST v1.1.	Baseline to study completion (up to 24 months)
Secondary	Duration of Response (DOR)	DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.	Baseline to study completion (up to 24 months)
Secondary	Disease Control Rate (DCR)	DCR is defined as the proportion of subjects achieving CR, PR, and SD after treatment.	Baseline to study completion (up to 24 months)
Secondary	Progression Free Survival (PFS)	PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.	Baseline to study completion (up to 24 months)
Secondary	Time to Response (TTR)	TTR is defined as the time from the start of treatment until the first occurrence of CR or PR by tumor assessment.	Baseline to study completion (up to 24 months)
Secondary	Overall Survival (OS)	OS is defined as the duration from the start of treatment to death of any cause.	Baseline to study completion (up to 24 months)
Secondary	PK parameters: concentration-time curve	Plot of drug concentration changing with time after drug administration.	Baseline to 90 days after the last dose.
Secondary	Immunogenicity (ADA)	The proportion of patients with positive ADA results.	Baseline to 90 days after the last dose.